• About Us
    • Company Overview
    • Leadership
    • Locations
  • Nelmastobart
    • Novel Immune-Checkpoint BTN1A1
    • Main Indications
  • R&D
    • Research Achievements
    • Pipeline
  • IR
    • Public Disclosure Information
    • Stock Price Information
    • IR Materials
  • PR
    • Press Release
    • Notices
  • Careers
    • Careers
  • Partnership
    • Partnership
ENG
  • KOR
  • ENG
  • About Us
    • Company Overview
    • Leadership
    • Locations
  • Nelmastobart
    • Novel Immune-Checkpoint BTN1A1
    • Main Indications
  • R&D
    • Research Achievements
    • Pipeline
  • IR
    • Public Disclosure Information
    • Stock Price Information
    • IR Materials
  • PR
    • Press Release
    • Notices
  • Careers
    • Careers
  • Partnership
    • Partnership
PR
STCube is dedicated to developing precision-driven immunotherapies,
bringing new hope to more cancer patients.
  • Press Release
  • Notices
Press Release
  • Press Release
  • Notices
Press Release
  • Home
  • PR
  • Press Release
  • 에스티큐브, 비소세포폐암 임상 2상 중간결과 발표…환자등록 73% 달성
    2026.10.27
  • 에스티큐브, ESMO서 넬마스토바트 3개 개발축 공개…병용 확장 전략 발표
    2026.10.14
  • [KBR] Nelmastobart could pair with osimertinib after clean EGFR safety..
    2026.09.16
  • [팍스경제TV] 에스티큐브, '넬마스토바트' 비소세포폐암의 새로운 치료 대안 기대감...'병용 안전성 강조'
    2026.09.16
  • 에스티큐브, 비소세포폐암 2상서 강력한 초기 효능 신호…ORR 26%, DCR 87%
    2026.09.15
  • [약업신문] 에스티큐브 유승한 미국대표 “EGFR 변이 폐암 2상 효능 첫 공개…ORR 37.5%·오시머티닙 병용 추진”
    2026.09.15
  • [딜사이트] 에스티큐브 ‘넬마스토바트’, 신기전 면역항암제로 급부상
    2026.09.15
  • [더벨] 에스티큐브 "넬마스토바트 폐암 첫 임상 안전성에 반응률"
    2026.09.14
  • 에스티큐브, WCLC서 넬마스토바트 비소세포폐암 임상 2상 초기 결과 발표
    2026.08.20
1 2 3 4 5

2201, Trade Center Trade Tower, 511 Yeongdong-daero, Gangnam-gu, Seoul, Republic of Korea

Tel : +82-2-551-3370

Copyright by STCube All Rights Reserved.